Growth Metrics

Gilead Sciences (GILD) FCF Margin (2009 - 2026)

Gilead Sciences posted quarterly FCF Margin of 34.87% for Q1 2026, up 1008.0% year-on-year from 3.15% in Q1 2025, and down 11.48% on a QoQ basis from 39.39% in Q4 2025.

Gilead Sciences (GILD) has 18 years of FCF Margin data on file, last reported at 34.87% in Q1 2026.

  • For the quarter ending Q1 2026, FCF Margin rose 1008.0% year-over-year to 34.87%; the trailing twelve-month figure through Mar 2026 stood at 34.4% (up 14.0% YoY), and the FY2025 full-year result was 32.12%, down 372.0% from the prior year.
  • FCF Margin for Q1 2026 stood at 34.87%, down from 39.39% in the prior quarter.
  • Across five years, FCF Margin topped out at 55.24% in Q3 2024 and bottomed at 10.17% in Q2 2025.
  • The 5-year median for FCF Margin is 31.62% (2024), against an average of 31.34%.
  • Peak annual rise in FCF Margin reached 3208 bps in 2024, while the deepest fall reached 1614 bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 32.29% in 2022, then declined by 15 bps to 27.47% in 2023, then soared by 36 bps to 37.36% in 2024, then climbed by 5 bps to 39.39% in 2025, then slipped by 11 bps to 34.87% in 2026.
  • The last three FCF Margin figures came in at 34.87% (Q1 2026), 39.39% (Q4 2025), and 50.98% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 15.19%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 6.09%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 23.76%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 17.97%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 17.14%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 34.87%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 93.16%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 6.59%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 34.87%
Dec 31, 2025 39.39%
Sep 30, 2025 50.98%
Jun 30, 2025 10.17%
Mar 31, 2025 24.79%
Dec 31, 2024 37.36%
Sep 30, 2024 55.24%
Jun 30, 2024 17.18%
Mar 31, 2024 31.62%
Dec 31, 2023 27.47%
Sep 30, 2023 23.16%
Jun 30, 2023 33.32%
Mar 31, 2023 25.74%
Dec 31, 2022 32.29%
Sep 30, 2022 38.43%
Jun 30, 2022 26.50%
Mar 31, 2022 24.17%
Dec 31, 2021 42.09%
Sep 30, 2021 41.96%
Jun 30, 2021 35.34%
Mar 31, 2021 38.07%
Dec 31, 2020 23.38%
Sep 30, 2020 31.85%
Jun 30, 2020 47.11%
Mar 31, 2020 22.80%
Dec 31, 2019 40.43%
Sep 30, 2019 43.63%
Jun 30, 2019 37.94%
Mar 31, 2019 25.37%
Dec 31, 2018 36.19%
Sep 30, 2018 36.54%
Jun 30, 2018 22.59%
Mar 31, 2018 40.45%
Dec 31, 2017 42.58%
Sep 30, 2017 39.39%
Jun 30, 2017 47.65%
Mar 31, 2017 43.15%
Dec 31, 2016 46.04%
Sep 30, 2016 55.93%
Jun 30, 2016 61.48%
Mar 31, 2016 50.72%
Dec 31, 2015 66.18%
Sep 30, 2015 45.93%
Jun 30, 2015 66.56%
Mar 31, 2015 73.44%
Dec 31, 2014 39.02%
Sep 30, 2014 64.70%
Jun 30, 2014 62.65%
Mar 31, 2014 28.09%
Dec 31, 2013 21.09%
Sep 30, 2013 25.72%
Jun 30, 2013 32.81%
Mar 31, 2013 25.01%
Dec 31, 2012 16.85%
Sep 30, 2012 27.97%
Jun 30, 2012 52.11%
Mar 31, 2012 18.83%
Dec 31, 2011 43.27%
Sep 30, 2011 39.25%
Jun 30, 2011 42.89%
Mar 31, 2011 41.83%
Dec 31, 2010 35.10%
Sep 30, 2010 37.60%
Jun 30, 2010 35.44%
Mar 31, 2010 31.59%
Dec 31, 2009 45.67%
Sep 30, 2009 46.76%
Jun 30, 2009 36.55%
Mar 31, 2009 31.18%